Short‐term cognitive practice effects and their relation to amyloid and tau in preclinical Alzheimer’s disease

Identification of cognitive paradigms that relate to biomarker evidence of Alzheimer’s disease (AD), such as tau, can greatly enhance patient selection for clinical trials. Computerized cognitive assessments that can be frequently administered may yield multiple unique variables that can improve detection of subtle cognitive decline in preclinical AD. Indeed, practice effects (i.e., improved performance on repeated testing) are diminished in clinically unimpaired older adults with abnormal amyloid, but their relations with tau are unknown. Here, we determine whether baseline performance and practice effects at 3 months re‐testing on the Computerized Cognitive Composite (C3) relate to medial temporal lobe (MTL) tau.